Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Scuoppo C, Wang J, Persaud M, Mittan SK, Basso K, Pasqualucci L, et al. Repurposing dasatinib for diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2019;116(34):16981-16986.

Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166-173.

Cohn CS, Allen ES, Cushing MM, Dunbar NM, Friedman DF, Goel R, et al. Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion. 2019;59(8):2733-2748.

Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, et al. Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer Cell. 2019;35(3):385-400.e9.

Canver MC, Satlin MJ, Westblade LF, Kreiswirth BN, Chen L, Robertson A, et al. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(9).

Barry DM, McMillan EA, Kunar B, Lis R, Zhang T, Lu T, et al. Molecular determinants of nephron vascular specialization in the kidney. Nat Commun. 2019;10(1):5705.

Cross T, Ransegnola B, Shin J-, Weaver A, Fauntleroy K, VanNieuwenhze MS, et al. Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. Antimicrob Agents Chemother. 2019;63(9).

Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol. 2019;249(1):79-89.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11(484).

Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.